scholarly article | Q13442814 |
P50 | author | Stephan Stilgenbauer | Q47158807 |
Peter Hillmen | Q48086375 | ||
Constantine S. Tam | Q55445006 | ||
William G Wierda | Q64026278 | ||
John C. Byrd | Q66429603 | ||
Susan M O'Brien | Q87633434 | ||
Jeffrey A Jones | Q87803317 | ||
Anthony Mato | Q89004907 | ||
Nyla A Heerema | Q89317565 | ||
Danelle F James | Q92176351 | ||
Cathy Zhou | Q104795915 | ||
Steven Coutre | Q114290920 | ||
Alvina D Chu | Q114341057 | ||
Fong Clow | Q114341062 | ||
P2093 | author name string | Anders Osterborg | |
Richard R Furman | |||
Karl Eckert | |||
P2860 | cites work | Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial | Q37633475 |
How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation? | Q38340201 | ||
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study | Q38956893 | ||
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial | Q39005118 | ||
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. | Q40474461 | ||
Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia | Q41848521 | ||
Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation | Q42208521 | ||
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia | Q46913558 | ||
Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis. | Q46916349 | ||
Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities | Q68535307 | ||
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 | ||
TP53 mutation and survival in chronic lymphocytic leukemia | Q27851577 | ||
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib | Q27853011 | ||
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group | Q31097476 | ||
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial | Q33412064 | ||
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial | Q33419580 | ||
Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. | Q33638819 | ||
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients | Q33821990 | ||
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia | Q34008593 | ||
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 | ||
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial | Q34141305 | ||
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study | Q34240404 | ||
Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia | Q35407650 | ||
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 | ||
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia | Q35903984 | ||
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens | Q36900364 | ||
Risk categories and refractory CLL in the era of chemoimmunotherapy | Q37141887 | ||
P433 | issue | 4 | |
P921 | main subject | ibrutinib | Q5984881 |
P304 | page(s) | 504-512 | |
P577 | publication date | 2018-06-05 | |
P1433 | published in | British Journal of Haematology | Q4970200 |
P1476 | title | Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials | |
P478 | volume | 182 |
Q91666607 | Chronic lymphocytic leukaemia: from genetics to treatment |
Q89694000 | Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma |
Q64092443 | First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013 |
Q93040664 | Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells |
Q89600801 | Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry |
Q92169106 | Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations |
Search more.